{"id":"https://openalex.org/W4401968708","doi":"https://doi.org/10.1177/10600280241271192","title":"Targeting GPRC5D With Talquetamab: A New Frontier in Bispecific Antibody Therapy for Relapsed/Refractory Multiple Myeloma","display_name":"Targeting GPRC5D With Talquetamab: A New Frontier in Bispecific Antibody Therapy for Relapsed/Refractory Multiple Myeloma","publication_year":2024,"publication_date":"2024-08-27","ids":{"openalex":"https://openalex.org/W4401968708","doi":"https://doi.org/10.1177/10600280241271192","pmid":"https://pubmed.ncbi.nlm.nih.gov/39192558"},"language":"en","primary_location":{"id":"doi:10.1177/10600280241271192","doi":"https://doi.org/10.1177/10600280241271192","is_oa":false,"landing_page_url":"https://doi.org/10.1177/10600280241271192","pdf_url":null,"source":{"id":"https://openalex.org/S113426163","display_name":"Annals of Pharmacotherapy","issn_l":"0012-6578","issn":["0012-6578","1060-0280","1542-6270"],"is_oa":false,"is_in_doaj":false,"is_core":true,"listed_in":["cwts-core","dongbi-b","doyens","jufo-1","ki-jl-1","medline","norway-1","poland-100","russia-white-list-2","vabb-shw"],"host_organization":"https://openalex.org/P4310320017","host_organization_name":"SAGE Publishing","host_organization_lineage":["https://openalex.org/P4310320017"],"host_organization_lineage_names":["SAGE Publishing"],"type":"journal"},"license":null,"license_id":null,"version":"publishedVersion","is_accepted":true,"is_published":true,"raw_source_name":"Annals of Pharmacotherapy","raw_type":"journal-article"},"volume":null,"type":"review","is_traditional":true,"indexed_in":["crossref","pubmed"],"open_access":{"is_oa":false,"oa_status":"closed","oa_url":null,"any_repository_has_fulltext":false},"authorships":[{"author_position":"first","author":{"id":"https://openalex.org/A5043159944","display_name":"Jacob Shaver","orcid":"https://orcid.org/0009-0007-3899-0010","observed_orcids":["https://orcid.org/0009-0007-3899-0010"]},"institutions":[{"id":"https://openalex.org/I155673605","display_name":"Union University","ror":"https://ror.org/02c561939","country_code":"US","type":"education","lineage":["https://openalex.org/I155673605"]}],"countries":["US"],"is_corresponding":false,"raw_author_name":"Jacob Shaver","raw_affiliation_strings":["College of Pharmacy, Union University, Jackson, TN, USA"],"raw_orcid":"https://orcid.org/0009-0007-3899-0010","affiliations":[{"raw_affiliation_string":"College of Pharmacy, Union University, Jackson, TN, USA","institution_ids":["https://openalex.org/I155673605"]}]},{"author_position":"middle","author":{"id":null,"display_name":"Daniel Horton","orcid":"https://orcid.org/0009-0005-2741-0549","observed_orcids":["https://orcid.org/0009-0005-2741-0549"]},"institutions":[{"id":"https://openalex.org/I155673605","display_name":"Union University","ror":"https://ror.org/02c561939","country_code":"US","type":"education","lineage":["https://openalex.org/I155673605"]}],"countries":["US"],"is_corresponding":false,"raw_author_name":"Daniel Horton","raw_affiliation_strings":["College of Pharmacy, Union University, Jackson, TN, USA"],"raw_orcid":"https://orcid.org/0009-0005-2741-0549","affiliations":[{"raw_affiliation_string":"College of Pharmacy, Union University, Jackson, TN, USA","institution_ids":["https://openalex.org/I155673605"]}]},{"author_position":"last","author":{"id":"https://openalex.org/A5020006994","display_name":"Zachery Halford","orcid":"https://orcid.org/0000-0002-7032-0398","observed_orcids":["https://orcid.org/0000-0002-7032-0398"]},"institutions":[{"id":"https://openalex.org/I155673605","display_name":"Union University","ror":"https://ror.org/02c561939","country_code":"US","type":"education","lineage":["https://openalex.org/I155673605"]}],"countries":["US"],"is_corresponding":true,"raw_author_name":"Zachery Halford","raw_affiliation_strings":["College of Pharmacy, Union University, Jackson, TN, USA"],"raw_orcid":"https://orcid.org/0000-0002-7032-0398","affiliations":[{"raw_affiliation_string":"College of Pharmacy, Union University, Jackson, TN, USA","institution_ids":["https://openalex.org/I155673605"]}]}],"institutions":[],"countries_distinct_count":1,"institutions_distinct_count":1,"corresponding_author_ids":["https://openalex.org/A5020006994"],"corresponding_institution_ids":["https://openalex.org/I155673605"],"apc_list":{"value":4200,"currency":"USD","value_usd":4200},"apc_paid":null,"fwci":0.5091,"has_fulltext":false,"cited_by_count":7,"citation_normalized_percentile":{"value":0.42914244,"is_in_top_1_percent":false,"is_in_top_10_percent":false},"cited_by_percentile_year":{"min":96,"max":97},"biblio":{"volume":"59","issue":"4","first_page":"350","last_page":"363"},"is_retracted":false,"is_paratext":false,"is_xpac":false,"primary_topic":{"id":"https://openalex.org/T10649","display_name":"Multiple Myeloma Research and Treatments","score":0.9984999895095825,"subfield":{"id":"https://openalex.org/subfields/2720","display_name":"Hematology"},"field":{"id":"https://openalex.org/fields/27","display_name":"Medicine"},"domain":{"id":"https://openalex.org/domains/4","display_name":"Health Sciences"}},"topics":[{"id":"https://openalex.org/T10649","display_name":"Multiple Myeloma Research and Treatments","score":0.9984999895095825,"subfield":{"id":"https://openalex.org/subfields/2720","display_name":"Hematology"},"field":{"id":"https://openalex.org/fields/27","display_name":"Medicine"},"domain":{"id":"https://openalex.org/domains/4","display_name":"Health Sciences"}},{"id":"https://openalex.org/T11016","display_name":"Monoclonal and Polyclonal Antibodies Research","score":0.0008999999845400453,"subfield":{"id":"https://openalex.org/subfields/2403","display_name":"Immunology"},"field":{"id":"https://openalex.org/fields/24","display_name":"Immunology and Microbiology"},"domain":{"id":"https://openalex.org/domains/1","display_name":"Life Sciences"}},{"id":"https://openalex.org/T12534","display_name":"Protein Degradation and Inhibitors","score":0.0,"subfield":{"id":"https://openalex.org/subfields/1312","display_name":"Molecular Biology"},"field":{"id":"https://openalex.org/fields/13","display_name":"Biochemistry, Genetics and Molecular Biology"},"domain":{"id":"https://openalex.org/domains/1","display_name":"Life Sciences"}}],"keywords":[{"id":"https://openalex.org/keywords/talquetamab","display_name":"talquetamab","score":0.925000011920929},{"id":"https://openalex.org/keywords/gprc5d","display_name":"GPRC5D","score":0.9470000267028809},{"id":"https://openalex.org/keywords/bispecific-antibodies","display_name":"bispecific antibodies","score":0.7860000133514404},{"id":"https://openalex.org/keywords/relapsed-refractory-multiple-myeloma","display_name":"relapsed/refractory multiple myeloma","score":0.9440000057220459},{"id":"https://openalex.org/keywords/t-cell-redirection","display_name":"T cell redirection","score":0.8880000114440918},{"id":"https://openalex.org/keywords/cytokine-release-syndrome","display_name":"cytokine release syndrome","score":0.8709999918937683},{"id":"https://openalex.org/keywords/immune-effector-cell-associated-neurotoxicity-syndrome","display_name":"immune effector cell-associated neurotoxicity syndrome","score":0.902999997138977},{"id":"https://openalex.org/keywords/dosing-regimen","display_name":"dosing regimen","score":0.6600000262260437},{"id":"https://openalex.org/keywords/treatment-safety","display_name":"treatment safety","score":0.4350000023841858}],"concepts":[{"id":"https://openalex.org/C71924100","wikidata":"https://www.wikidata.org/wiki/Q11190","display_name":"Medicine","level":0,"score":0.9410997629165649},{"id":"https://openalex.org/C2777288759","wikidata":"https://www.wikidata.org/wiki/Q4164182","display_name":"Dosing","level":2,"score":0.6436207294464111},{"id":"https://openalex.org/C535046627","wikidata":"https://www.wikidata.org/wiki/Q30612","display_name":"Clinical trial","level":2,"score":0.6272437572479248},{"id":"https://openalex.org/C126322002","wikidata":"https://www.wikidata.org/wiki/Q11180","display_name":"Internal medicine","level":1,"score":0.5604467391967773},{"id":"https://openalex.org/C197934379","wikidata":"https://www.wikidata.org/wiki/Q2047938","display_name":"Adverse effect","level":2,"score":0.5502573847770691},{"id":"https://openalex.org/C2776364478","wikidata":"https://www.wikidata.org/wiki/Q467635","display_name":"Multiple myeloma","level":2,"score":0.5350965261459351},{"id":"https://openalex.org/C72563966","wikidata":"https://www.wikidata.org/wiki/Q1303415","display_name":"Cohort","level":2,"score":0.48228195309638977},{"id":"https://openalex.org/C143998085","wikidata":"https://www.wikidata.org/wiki/Q162555","display_name":"Oncology","level":1,"score":0.4715713858604431},{"id":"https://openalex.org/C2777054765","wikidata":"https://www.wikidata.org/wiki/Q6402731","display_name":"Dysgeusia","level":3,"score":0.4393627643585205},{"id":"https://openalex.org/C2780850621","wikidata":"https://www.wikidata.org/wiki/Q3961647","display_name":"Cytokine release syndrome","level":5,"score":0.4361114203929901},{"id":"https://openalex.org/C142424586","wikidata":"https://www.wikidata.org/wiki/Q7307572","display_name":"Refractory (planetary science)","level":2,"score":0.4332422912120819},{"id":"https://openalex.org/C2777701055","wikidata":"https://www.wikidata.org/wiki/Q1427096","display_name":"Immunotherapy","level":3,"score":0.3161407709121704},{"id":"https://openalex.org/C121608353","wikidata":"https://www.wikidata.org/wiki/Q12078","display_name":"Cancer","level":2,"score":0.25784462690353394},{"id":"https://openalex.org/C3875195","wikidata":"https://www.wikidata.org/wiki/Q5099363","display_name":"Chimeric antigen receptor","level":4,"score":0.14998579025268555},{"id":"https://openalex.org/C87355193","wikidata":"https://www.wikidata.org/wiki/Q411","display_name":"Astrobiology","level":1,"score":0.0},{"id":"https://openalex.org/C121332964","wikidata":"https://www.wikidata.org/wiki/Q413","display_name":"Physics","level":0,"score":0.0}],"mesh":[{"descriptor_ui":"D006801","descriptor_name":"Humans","qualifier_ui":null,"qualifier_name":null,"is_major_topic":false},{"descriptor_ui":"D009101","descriptor_name":"Multiple Myeloma","qualifier_ui":"Q000188","qualifier_name":"drug therapy","is_major_topic":true},{"descriptor_ui":"D018033","descriptor_name":"Antibodies, Bispecific","qualifier_ui":"Q000008","qualifier_name":"administration & dosage","is_major_topic":true},{"descriptor_ui":"D018033","descriptor_name":"Antibodies, Bispecific","qualifier_ui":"Q000009","qualifier_name":"adverse effects","is_major_topic":true},{"descriptor_ui":"D018033","descriptor_name":"Antibodies, Bispecific","qualifier_ui":"Q000494","qualifier_name":"pharmacology","is_major_topic":true},{"descriptor_ui":"D018033","descriptor_name":"Antibodies, Bispecific","qualifier_ui":"Q000627","qualifier_name":"therapeutic use","is_major_topic":true},{"descriptor_ui":"D043562","descriptor_name":"Receptors, G-Protein-Coupled","qualifier_ui":"Q000037","qualifier_name":"antagonists & inhibitors","is_major_topic":true},{"descriptor_ui":"D043562","descriptor_name":"Receptors, G-Protein-Coupled","qualifier_ui":"Q000276","qualifier_name":"immunology","is_major_topic":true}],"locations_count":2,"locations":[{"id":"doi:10.1177/10600280241271192","doi":"https://doi.org/10.1177/10600280241271192","is_oa":false,"landing_page_url":"https://doi.org/10.1177/10600280241271192","pdf_url":null,"source":{"id":"https://openalex.org/S113426163","display_name":"Annals of Pharmacotherapy","issn_l":"0012-6578","issn":["0012-6578","1060-0280","1542-6270"],"is_oa":false,"is_in_doaj":false,"is_core":true,"listed_in":["cwts-core","dongbi-b","doyens","jufo-1","ki-jl-1","medline","norway-1","poland-100","russia-white-list-2","vabb-shw"],"host_organization":"https://openalex.org/P4310320017","host_organization_name":"SAGE Publishing","host_organization_lineage":["https://openalex.org/P4310320017"],"host_organization_lineage_names":["SAGE Publishing"],"type":"journal"},"license":null,"license_id":null,"version":"publishedVersion","is_accepted":true,"is_published":true,"raw_source_name":"Annals of Pharmacotherapy","raw_type":"journal-article"},{"id":"pmid:39192558","doi":null,"is_oa":false,"landing_page_url":"https://pubmed.ncbi.nlm.nih.gov/39192558","pdf_url":null,"source":{"id":"https://openalex.org/S4306525036","display_name":"PubMed","issn_l":null,"issn":null,"is_oa":false,"is_in_doaj":false,"is_core":false,"listed_in":[],"host_organization":"https://openalex.org/I1299303238","host_organization_name":"National Institutes of Health","host_organization_lineage":["https://openalex.org/I1299303238"],"host_organization_lineage_names":[],"type":"repository"},"license":null,"license_id":null,"version":"publishedVersion","is_accepted":true,"is_published":true,"raw_source_name":"The Annals of pharmacotherapy","raw_type":"Journal Article"}],"best_oa_location":null,"sustainable_development_goals":[{"id":"https://metadata.un.org/sdg/3","display_name":"Good health and well-being","score":1.0}],"study_designs":[],"awards":[],"funders":[],"has_content":{"grobid_xml":false,"pdf":false},"content_urls":null,"referenced_works_count":37,"referenced_works":["https://openalex.org/W1832162035","https://openalex.org/W1910012553","https://openalex.org/W1965679187","https://openalex.org/W1999130958","https://openalex.org/W2082708772","https://openalex.org/W2592173429","https://openalex.org/W2604776612","https://openalex.org/W2763751953","https://openalex.org/W2905654445","https://openalex.org/W2954506039","https://openalex.org/W2971490864","https://openalex.org/W2999052236","https://openalex.org/W3001767756","https://openalex.org/W3005994291","https://openalex.org/W3021927596","https://openalex.org/W3130050285","https://openalex.org/W3133229959","https://openalex.org/W3154427589","https://openalex.org/W3162374648","https://openalex.org/W3211326091","https://openalex.org/W3214016346","https://openalex.org/W4210734847","https://openalex.org/W4237659442","https://openalex.org/W4281714381","https://openalex.org/W4282033105","https://openalex.org/W4297519419","https://openalex.org/W4310106497","https://openalex.org/W4312072518","https://openalex.org/W4322730657","https://openalex.org/W4378800539","https://openalex.org/W4385644682","https://openalex.org/W4385644849","https://openalex.org/W4385839624","https://openalex.org/W4386324983","https://openalex.org/W4386332461","https://openalex.org/W4389231964","https://openalex.org/W4390946922"],"related_works":["https://openalex.org/W7197030156","https://openalex.org/W4410810143","https://openalex.org/W4286294116","https://openalex.org/W4416724262","https://openalex.org/W4312072518","https://openalex.org/W3209765086","https://openalex.org/W4401876394","https://openalex.org/W4283328367","https://openalex.org/W4405050267","https://openalex.org/W4310106497"],"abstract_inverted_index":{"OBJECTIVE:":[0],"To":[1],"evaluate":[2],"the":[3,20,58,69,96,106,187,205,217],"pharmacology,":[4],"clinical":[5,11,40,74,169,199],"efficacy,":[6],"safety,":[7],"dosing,":[8],"administration,":[9],"and":[10,33,43,49,62,102,121,126,193,211],"implications":[12],"of":[13,22,82,165,214,222],"talquetamab-tgvs,":[14],"a":[15,140,148],"novel":[16],"bispecific":[17,144],"antibody,":[18,145],"in":[19,85,95,105,186,216],"treatment":[21,150,220],"relapsed":[23],"or":[24],"refractory":[25],"(R/R)":[26],"multiple":[27],"myeloma":[28],"(MM).":[29],"DATA":[30,37,51],"SOURCES:":[31],",":[32],"STUDY":[34],"SELECTION":[35],"AND":[36,136],"EXTRACTION:":[38],"Relevant":[39],"trials,":[41],"guidelines,":[42],"prescribing":[44],"information":[45],"were":[46],"systematically":[47],"reviewed":[48],"analyzed.":[50],"SYNTHESIS:":[52],"Talquetamab-tgvs":[53],"received":[54,159],"accelerated":[55],"approval":[56],"from":[57,68],"United":[59],"States":[60],"Food":[61],"Drug":[63],"Administration":[64],"based":[65],"on":[66],"results":[67],"pivotal":[70,188],"phase":[71],"I/II":[72],"MonumenTAL-1":[73,189],"trial,":[75,190],"which":[76],"demonstrated":[77],"an":[78],"overall":[79,212],"response":[80],"rate":[81],"nearly":[83],"74%":[84],"key":[86],"cohorts.":[87],"The":[88],"median":[89],"progression-free":[90],"survival":[91],"was":[92],"7.5":[93],"months":[94,104],"0.4":[97],"mg/kg":[98,108],"weekly":[99],"dosing":[100,110],"cohort":[101],"11.9":[103],"0.8":[107],"biweekly":[109],"cohort.":[111],"Treatment-related":[112],"adverse":[113],"events":[114],"(AEs)":[115],"included":[116],"cytokine":[117],"release":[118],"syndrome,":[119],"skin-":[120],"nail-related":[122],"AEs,":[123],"dysgeusia,":[124],"infections,":[125],"immune":[127],"effector":[128],"cell-associated":[129],"neurotoxicity":[130],"syndrome.":[131],"RELEVANCE":[132],"TO":[133],"PATIENT":[134],"CARE":[135],"CLINICAL":[137],"PRACTICE:":[138],"As":[139],"first-in-class":[141],"anti-GPRC5D":[142],"T-cell-redirecting":[143,178],"talquetamab-tgvs":[146,175,182,215],"represents":[147],"compelling":[149],"option":[151],"for":[152],"patients":[153],"with":[154],"R/R":[155,223],"MM":[156],"who":[157],"have":[158,171],"at":[160],"least":[161],"4":[162],"prior":[163],"lines":[164],"therapy.":[166],"No":[167],"head-to-head":[168],"trials":[170,200],"been":[172],"conducted":[173],"comparing":[174],"to":[176,203],"other":[177],"therapies.":[179],"CONCLUSIONS:":[180],"While":[181],"showed":[183],"significant":[184],"efficacy":[185,194],"long-term":[191],"safety":[192],"data":[195],"are":[196,201],"needed.":[197],"Additional":[198],"necessary":[202],"establish":[204],"optimal":[206],"timing,":[207],"sequencing,":[208],"patient":[209],"population,":[210],"role":[213],"rapidly":[218],"evolving":[219],"landscape":[221],"MM.":[224]},"counts_by_year":[{"year":2026,"cited_by_count":3},{"year":2025,"cited_by_count":4}],"updated_date":"2026-11-10T11:39:43.021295","created_date":"2024-08-29T00:00:00"}